Join our daily newsletter At The Bell to receive exclusive market insights
- Biopharmaceutical company Immuron (IMC) sees a 494 per cent increase in North American Travelan sales for FY22
- Sales totalled $600,000 for the financial year, up from the $100,000 recorded in FY21 while US sales were up from the $4000 recorded in FY21
- Global sales of Travelan and Protectyn – a supplement that targets and removes bacteria in the gut – increased 431 per cent from $200,000 in FY21 to $900,000 in FY22
- Notably in Australia, Travelan and Protectyn sales increased to $300,000 in FY22 from $100,000 in FY21
- Shares in Immuron ended the day 3.41 per cent in the green to close at 9.1 cents
Biopharmaceutical company Immuron (IMC) has seen a 494 per cent increase in North American Travelan sales for FY22.
Sales totalled $600,000 for the financial year, up from the $100,000 recorded in FY21 while US sales were up from the $4000 recorded in FY21.
Immuron credits this growth to increasing sales in passport health travel clinics as well as on Amazon’s e-commerce channel.
While sales are currently not at their pre-pandemic peak, sales in the US are starting to pick up.
Travelan is an orally administered passive immunotherapy that reduces the likelihood of contracting travellers’ diarrhoea when visiting developing countries.
Global sales of Travelan and Protectyn – a supplement that targets and removes harmful bacteria and toxins in the gut – increased 431 per cent from $200,000 in FY21 to $900,000 in FY22.
Notably in Australia, Travelan and Protectyn sales increased to $300,000 in FY22 from $100,000 in FY21.
After coming out of Government-imposed restrictions and international travel resuming, retail stores in Australia are beginning to restock the products.
Shares in Immuron ended the day 3.41 per cent in the green to close at 9.1 cents.
